Vaxcyte(PCVX) - 2023 Q4 - Annual Results

Exhibit 99.1 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Program and End-of-Phase 2 Meeting; VAX-24 is Phase 3-Ready in Adults -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- Enrollment in V ...